Antidepressant treatment and suicide attempts and self-inflicted injury in children and adolescents

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 2, 2015, Pages 208-214

  Gibbons, Robert D ^a   Coca Perraillon, Marcelo ^b   Hur, Kwan ^a   Conti, Rena M ^b   Valuck, Robert J ^c   Brent, David A ^d  

^a University of Chicago   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Children and adolescents; Marginal structural models; Pharmacoepidemiology; Self inflicted injury; Suicide attempts; Time varying confounding

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT;

ADOLESCENT; ADOLESCENT BEHAVIOR; ARTICLE; AUTOMUTILATION; CHILD; CHILD BEHAVIOR; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DEPRESSION; DISEASE ASSOCIATION; FEMALE; HIGH RISK BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; RISK FACTOR; SUICIDE ATTEMPT; SURVIVAL TIME; BIOLOGICAL MODEL; EPIDEMIOLOGY; FACTUAL DATABASE; RETROSPECTIVE STUDY; SELF-INJURIOUS BEHAVIOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; DATABASES, FACTUAL; HUMANS; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; RISK FACTORS; SELF-INJURIOUS BEHAVIOR; SUICIDE, ATTEMPTED; UNITED STATES;

EID: 84921654779     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3713     Document Type: Article

References (30)

1. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096352.htm. Accessed 9/5/2014.
2. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332-9.
3. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297(15): 1683-96.
4. Simon GE, Savarino J, Operskalski B. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163: 41-7.
5. Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 2007; 164(7): 1029-34.
6. Valuck RJ, Libby AM, Sills MR, et al. Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 2004; 18: 1119-32.
7. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults. Arch Gen Psychiatry 2006; 63: 865-72.
8. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006; 63: 1358-67.
9. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: Synthesis of 6-week patient-level outcomes from double-blind placebo controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012a; 69: 572-9.
10. Gibbons RD, Brown CH, Hur K, Davis JM, Mann JJ. Suicidal thoughts and behavior with antidepressants treatment: Re-analysis of the Randomized Placebo Controlled Studies of Fluoxetine and Venlafaxine. Arch Gen Psychiatry 2012b; 69: 580-7.
11. Conwell Y, Brent D. Suicide and aging. I: Patterns of psychiatric diagnosis. Int Psychogeriatr 1995; 7(2): 149-64.
12. McGirr A, Renaud J, Bureau A, Seguin M, Lesage A, Turecki G. Impulsive-aggressive behaviours and completed suicide across the life cycle: a predisposition for younger age of suicide. Psychol Med 2008; 38(3): 407-17.
13. Brent D, Melhem N, Turecki G. Pharmacogenomics of suicidal events. Pharmacogenomics 2010; 11(6): 793-807.
14. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009; 166(4): 418-26.
15. Gibbons RD, Mann JJ. Strategies for quantifying the relationship between medications and suicidal behavior: what has been learned? Drug Saf 2011; 34: 375-95.
16. Goldsmith SK, Pellmar TC, Kleinman AM, et al. Reducing Suicide: A National Imperative. National Academy Press: Washington D.C., 2002.
17. Robins JM, Hernán MA, Brumback B. Marginal Structural Models and Causal Inference in Epidemiology. Epidemiology 2000; 11: 550-60.
18. Efron B. Logistic regression, survival analysis, and the Kaplan Meier curve. J Am Stat Assoc 1988; 83: 414-25.
19. Gibbons RD, Duan N, Meltzer D, et al. Waiting for organ transplantation: results of an analysis by Institute of Medicine Committee. Biostatistics 2003; 4: 207-22.
20. Hedeker D, Gibbons RD. Longitudinal Data Analysis. Wiley: New York, 2006.
21. Rosenbaum P, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-50.
22. Bowie MJ, Schaffer RM. Understanding ICD-10-CM and ICD-10-PCS: A Worktext. Clifton Park. Delmar Cengage Learning: NY, 2011.
23. Robins JM, Greenland S, Hu F-C. Estimation of the causal effect of a time-varying exposure on the marginal mean of a repeated binary outcome. J Am Stat Assoc 1999; 94: 687-700.
24. Barrett M, Steiner C, Coben J. Healthcare Cost and Utilization Project (HCUP) E Code Evaluation Report. HCUP Methods Series Report # 2004-06 ONLINE. April 14, 2005. US Agency for Healthcare Research and Quality 2004. http://www.hcup-us.ahrq.gov/reports/methods/2004_6.pdf [9/5/2014].
25. Delaney JAC, Daskaloppulou MD, Stella S, Suissa S. Traditional versus marginal structural models to estimate the effectiveness of β-blocker use on mortality after myocardial infarction. Pharmacoepidemiol Drug Saf 2008; 18: 1-6.
26. Yang W, Joffe MM. Subtle issues in model specification and estimation of marginal structural models. Pharmacoepidemiol Drug Saf 2012; 21: 241-5.
27. Miller JE, Molnar MZ, Kovesdy CP. Administered paricalcitol dose and survival in hemodialysis patients: A marginal structural model analysis. Pharmacoepidemiol Drug Saf 2012; 21: 1232-9.
28. Cook NR, Cole SR, Hennekens CH, et al. Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J of Epidemiology 2002; 1(55): 1045-53.
29. Toh S, Manson JE. An Analytic Framework for Aligning Observational and Randomized Trial Data: Application to Postmenopausal Hormone Therapy and Coronary Heart Disease. Statistics in Biosciences 2012; October: 1-17.
30. Valenstein M, Kim HM, Ganoczy D, et al. Antidepressant agents and suicide Death among US Department of Veterans Affairs Patients in Depression Treatment. J Clin Psychopharmacol 2012; 32(3): 346-353. doi:10.1097/JCP.0b013e3182539f11